How a Weak Dollar and Tanking Trends Made It Hard for the Raptors?
The Toronto Raptors, the NBA's only Canadian franchise, have a steep financial challenge for the 2025–26 season. A weak Canadian dollar has squeezed their budget, with $175 million (U.S.) already committed to 10 players.
The exchange rate reduces the value of Canadian revenue, tickets, sponsorships, and others, when it is converted to U.S. dollars, the currency the NBA pays salaries with. This gap makes every contract costlier, squeezing the team's ability to spend wisely. It only remains to be seen how the front office will tackle these issues for the next season, while the fans can only speculate and follow the odds that well-established sportsbooks like Bet365 provide, as they offer very competitive odds and a user friendly interface design on both the app and the site, as mentioned in this bet365 review. Luxury Tax Tightrope
Staying below the NBA's luxury tax threshold adds another layer of difficulty. The luxury tax kicks in when teams exceed a set spending limit, and the penalties can pile up fast. For the Raptors, filling out the roster with the remaining spots, likely three to five players, means hunting for bargains, which carries its own set of risks.
Cheap, young talent or veteran minimum deals might help, but quality options are scarce, and the weak dollar shrinks their buying power, risking a thinner, less competitive lineup. The Tanking Allegation
Across the NBA, about a third of the league faces tanking accusations, deliberately losing games to snag better draft picks. Teams sit star players or quietly shift focus to development over wins.
The Raptors aren't openly tanking, but their recent struggles spark speculation. Historically, team president Masai Ujiri has favored building from the middle—crafting a playoff contender without bottoming out. Yet, a tough 2025–26 season, combined with financial strain, fuels debate about whether a subtle tank might be in play. A Challenging Path Ahead
The Raptors stand at a crossroads. The weak Canadian dollar limits their financial flexibility, while the luxury tax looms large. Tanking trends in the NBA tempt struggling teams, but Toronto's legacy leans toward resilience.
Balancing a competitive roster, a tight budget, and the lure of a high draft pick tests the front office. For Canada's only NBA squad, the 2025–26 season promises a fight to stay afloat in choppy waters.
Originally published on sportsworldnews.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Int'l Business Times
10 hours ago
- Int'l Business Times
Sahel Juntas Pile Pressure On Foreign Mining Firms
Army strongmen who have seized power in coups across Africa's Sahel region since 2020 have ramped up pressure on foreign mining companies in the name of greater control over their countries' riches. Niger's nationalisation of the local branch of French uranium giant Orano on Thursday is the latest such measure by the junta and its allies in Burkina Faso and Mali. In particular the coup-hit trio, which have all turned their backs on their shared former colonial master France in favour of stronger ties with Russia, have placed Western firms firmly in their sights. Niger's nationalisation of Orano's local branch Somair has brought a months-long struggle with the French firm to a peak. Orano, which is 90-percent owned by the French state, had already admitted to having lost operational control of its subsidiary months ago. Meanwhile in Mali, Canadian giant Barrick Mining is locked in a tug-of-war with the army over a mining code that came into force in 2023. The military is demanding hundreds of millions of dollars of back taxes from the firm. Barrick has since lost control of Loulo-Gounkoto, the country's largest gold mine, in which the Canadian firm holds a majority stake. In November 2024, Malian soldiers arrested the director of Australia's Resolute Mining, along with two employees. All were subsequently released after Resolute agreed to pay the junta $160 million in exchange. Other mine companies such as Canada's allied Gold, B2Gold and Robex had previously agreed to review their activities and pay to settle their tax or customs dispute. And in 2023 Burkina Faso seized 200 kilograms (440 pounds) of gold produced by a branch of Canada's Endeavour Mining on "public necessity" grounds. For the juntas, the point of the push against foreign mining companies is to reestablish sovereignty and control over their national resources. Where they believed the Sahel's resource riches were previously sold out to foreigners, and to the West in particular, today the army leaders promise their people that ordinary citizen will receive a greater share of the profits from the wealth under their feet. Niger produces nearly five percent of the world's uranium. Gold makes up a quarter of Mali's national budget. And Burkina Faso's gold production contributes around 14 percent of the country's revenues, according to official statistics. "The population sees this as a push to free states which were previously, according to the new authorities, subservient to Westerners and therefore foreign interests," said Jeremie Taieb, director of consulting firm Tikva Partners. This rejection therefore "helps to satisfy public opinion and nurtures a narrative that allows those in power to keep it", Taieb added. All three countries are plagued by jihadist violence, which has claimed thousands of lives across the region. Besides economic sanctions imposed on the juntas in the wake of the coups, "the pressures exerted to fund the fight against terrorism" provide as good a reason as any "to extract more income from the sector", said Beverly Ochieng, an analyst at Control Risks. To fight back against the juntas, the mining industry has looked to international arbitration. Barrick has turned to the International Centre for Settlement of Investment Disputes (ICSID), part of the Washington-based World Bank. France's Orano has launched various lawsuits against the state of Niger, accusing the junta of a "systematic policy of stripping mining assets". In a statement Friday evening, the day after Niger announced its intention to nationalise its subsidiary, the firm said it "intends to claim compensation for all of its damages and assert its rights over the stock corresponding to Somair's production to date". For Taieb, this "legal instability" in the Sahel could drive investors towards countries with a more reliable business backdrop. But for Control Risks' Ochieng, "foreign firms will probably continue to engage with administrations in the Sahel... as mining assets represent a hefty and long-term investment". In any case the countries that stand to gain most from the current climate are Mali, Niger and Burkina Faso's so-called "security partners" -- especially Turkey, China and Russia. On Monday, Mali and Russia began construction work on a new gold refinery in the Malian capital Bamako. Moscow has also sent mercenaries from its paramilitary Africa Corps to the Sahel country to help fight jihadists. For the Russians, the deal is "minerals for weapons, in the same way that for the Chinese, it's minerals for infrastructure", said Taieb.
Int'l Business Times
2 days ago
- Int'l Business Times
Lakers To Be Sold In Record-breaking $10 Billion Deal: ESPN
The Los Angeles Lakers are being sold in a record-breaking $10 billion deal that makes the iconic franchise the highest-valued sports team in US history, ESPN reported Wednesday. The report said the Lakers owners, the Buss family, would sell their controlling interest in the team to billionaire Mark Walter, who already owns a stake in the franchise. While Jeanie Buss would continue as Lakers governor, the deal ends the Buss family's 47-year reign over the NBA giants. Walter is the chief executive of holding company TWG Global which has built an impressive portfolio of professional sports teams, including the Los Angeles Dodgers and Los Angeles Sparks. TWG also owns the Billie Jean King Cup tennis tournament and the Cadillac Formula One team. While further specifics of the deal were not disclosed, Lakers legend Magic Johnson -- a business partner of Walter -- was among the first to react to news of the agreement. "Laker fans should be ecstatic," Johnson wrote on X. "A few things I can tell you about Mark - he is driven by winning, excellence, and doing everything the right way. And he will put in the resources needed to win! I can understand why Jeanie sold the team to Mark Walter because they are just alike." Johnson cited Walter's ownership of the Los Angeles Dodgers baseball team as a reason for optimism. The Dodgers have won the World Series twice since Walter's ownership group took the club over. "Mark is the best choice and will be the best caretaker of the Laker brand," Johnson wrote. "The proof is in the pudding on what he's been able to accomplish with the LA Dodgers. Mark has been nothing short of a winner." The end of the Buss family's control of the Lakers marks the end of an era in the NBA. The team were bought by charismatic tycoon Jerry Buss in 1979, who quickly helped turn the franchise into a sporting powerhouse as well as a globally recognised brand. The Buss era brought the Lakers 11 NBA championships -- more than any other team over the same period -- and encompassed golden ages which included the "Showtime" Lakers of Magic Johnson as well as a hat-trick of championships between 2000-2002 when the team was spearheaded by Kobe Bryant. Walter has been a minority owner of the Lakers since 2021 when he bought a share of the team in a deal which also gave him first refusal to buy the club should the Buss family ever decide to sell. The sale of the club smashes the previous highest figure paid for a US sports team, the $6.1 billion paid for the Boston Celtics earlier this year. That Celtics sale eclipsed the $6.05 billion that Josh Harris paid for the Washington Commanders in 2023.
Int'l Business Times
2 days ago
- Int'l Business Times
Passion, Plants, and Phase III: Devonian Health Group Is on a Mission to Disrupt Inflammation Therapy
While the industry might be dominated by synthetic compounds, billion-dollar VC funds, and long, uncertain development timelines, Devonian Health Group Inc. is proving there is another way. As a publicly traded company, under the leadership of its founder and CEO, Dr. André P. Boulet, Devonian has quietly advanced multi-target drug candidates and a cutting-edge cosmeceutical line, backed not by institutional investors but by a network of Canadian family offices made up of dentists, physicians, engineers, and entrepreneurs. Boulet's journey to this unconventional success story reads like a masterclass in risk, reinvention, and scientific conviction. "I'm a venture capitalist in my heart," Boulet says. "But I'm also a scientist. When I saw the anti-inflammatory results of this botanical extract technology from a university agriculture project, I knew this had real potential. So, I followed my instinct and took the risk." With a PhD in physiology-endocrinology, postdoctoral training in biochemistry and biophysics, and experience leading cardiovascular clinical research programs, Boulet's transition from academia to venture capital was swift. After climbing the pharmaceutical ladder and managing funds in Montreal, he exited his partnership and launched what would become Devonian Health Group in 2015. At its core, Devonian is a clinical-stage pharmaceutical company focused on autoimmune and inflammatory conditions, with its lead drug candidate, Thykamine ™, poised to enter Phase III clinical trials for atopic dermatitis and soon pediatric eczema. "Traditional pharma was built on the 'silver bullet,' one target, one mechanism," Boulet explains. "But now science is evolving. We're moving toward therapies that modulate multiple pathways. That's exactly what Thykamine does without shutting down important immune functions like TNF-alpha. That's why our efficacy is high, but side effects are minimal." What sets Devonian apart isn't just its marquee drug but the platform behind it. The company's patented SUPREX™ technology allows for water-based extraction, purification, and stabilization of Active Botanical Ingredients (ABIs) from plants and algae. These complexes modulate inflammation at the genetic level across multiple diseases, offering a broad pipeline of possibilities. To date, Thykamine™ has demonstrated strong results in its Phase II trial. Both gastrointestinal (ulcerative colitis) and dermatological (eczema) models have shown significant symptom relief and safety comparable to placebo. Remarkably, all this has been achieved without traditional VC backing. Boulet credits this to his deep network of entrepreneurial allies and his belief in business-first partnerships. "We've raised funds to advance to Phase III, built an extraction and production facility, and kept the company debt-free," he says. While the pharmaceutical arm garners headlines, Devonian's cosmeceutical division is equally ambitious. Operating under the Purgenesis™ brand, the company has developed a premium line of anti-aging creams containing its patented botanical ingredient R-Spinasome®, a photosynthetic cell extract with dynamic antioxidant properties. What makes Purgenesis™ unusual in the beauty space is its clinical rigor. Devonian has conducted peer-reviewed, pharma-grade clinical trials on the entire product line, something virtually unheard of in the cosmeceutical industry. "We've scientifically proven a reduction in wrinkles," says Boulet. "Not just pretty pictures, but peer-reviewed, published data. We're the only ones doing cosmeceuticals the pharma way." With day, night, and eye creams already developed and a professional-grade serum in the pipeline, Devonian is currently seeking commercial partners to bring Purgenesis™ to a global market hungry for results-backed skincare. Perhaps the most unusual aspect of Devonian's success is how personal it all feels. There are no Silicon Valley investors or hedge fund suits behind the curtain, just a network of entrepreneurs who believe in the mission. "Working with family offices is stimulating," Boulet says. "You get input from pharmacists, dentists, and industrialists. We face challenges together, and we have fun doing it." The company's headquarters in Québec includes a full-scale extraction and production facility, providing complete traceability from seed to pill. This vertical integration helps with both cutting costs, yes, but also ensuring product consistency. For Boulet, the journey has been one of passion and perseverance. "In life, there's always a risk," he reflects. "But if you surround yourself with the right people and believe in what you're building, that risk becomes your fuel. That's what Devonian is about: science, instinct, and community." As the company readies for Phase III trials in both pharmaceuticals and final-stage commercialization of its skincare line, Devonian Health Group stands as a testament to the power of conviction and the potential of plants to reshape the future of medicine.
